|
Oct 1
|
Chemomab Therapeutics to Present at October 2024 Investor Conferences
|
|
Aug 28
|
Chemomab Therapeutics to Present at September 2024 Investor Conferences
|
|
Jul 30
|
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
|
|
Jul 26
|
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
|
|
Jul 25
|
Chemomab Therapeutics Announces $10 Million Private Placement
|
|
Jul 25
|
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
|
|
Jun 18
|
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
|
|
May 17
|
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
|
|
Feb 20
|
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
|
|
Aug 29
|
Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
|
|
Apr 26
|
Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference
|